Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response. We have previously showed that low-dose DNA demethylating agent decitabine therapy promotes CD3+ T-cell proliferation and cy...

Full description

Bibliographic Details
Main Authors: Xiang Li, Liang Dong, Jiejie Liu, Chunmeng Wang, Yan Zhang, Qian Mei, Weidong Han, Ping Xie, Jing Nie
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
decitabine
CD4+ T cells
immune response
NF-κB activation
IκBα degradation
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.647713/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.647713/full

Similar Items